Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Key Points

• Chardan Capital reaffirmed its Buy rating on Coya Therapeutics and set a $14 price target, implying approximately 192% upside from the prior close.
• Analyst sentiment is generally positive, with six Buy ratings and one Sell rating; the consensus view is “Moderate Buy” with an average price target of $15.33.
• Coya reported quarterly EPS of negative $0.28, beating estimates of negative $0.35, while revenue of $0.22 million exceeded the $0.13 million consensus estimate. Institutional investors own approximately 39.75% of the company.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at Chardan Capital in a research note issued on Wednesday,Benzinga reports. They presently have a $14.00 price objective on the stock. Chardan Capital's target price would indicate a potential upside of 191.67% from the stock's previous close.

Other analysts have also issued reports about the stock. Wall Street Zen lowered shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Coya Therapeutics in a research note on Friday, July 17th. Finally, Roth Capital started coverage on Coya Therapeutics in a research report on Friday, June 5th. They issued a "buy" rating and a $12.00 price target on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Coya Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $15.33.

Coya Therapeutics Trading Up 3.4%

Shares of NASDAQ COYA opened at $4.80 on Wednesday. The business has a fifty day simple moving average of $4.86 and a 200 day simple moving average of $4.67. The firm has a market capitalization of $112.61 million, a price-to-earnings ratio of -4.17 and a beta of 0.60. Coya Therapeutics has a one year low of $3.71 and a one year high of $7.75.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.07. The firm had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.13 million. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%. On average, research analysts anticipate that Coya Therapeutics will post -1.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. acquired a new stake in shares of Coya Therapeutics during the third quarter worth $28,000. CIBC Private Wealth Group LLC acquired a new position in Coya Therapeutics in the fourth quarter valued at about $47,000. Occudo Quantitative Strategies LP bought a new position in Coya Therapeutics during the fourth quarter worth about $66,000. Oppenheimer & Co. Inc. bought a new position in Coya Therapeutics during the fourth quarter worth about $81,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in Coya Therapeutics during the second quarter worth about $119,000. Institutional investors and hedge funds own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source